|BioCryst Pharmaceuticals Inc -- USA Stock|| |
USD 5.2 0.12 2.36%
Sr. VP of Drug Discovery
Dr. Yarlagadda S. Babu, Ph.D., is Senior Vice President Drug Discovery of the company since October 2013. Dr. Babu was the Vice President Drug Discovery of Biocryst Pharmaceuticals Inc. He joined BioCryst in 1988 and was BioCrysts first fulltime employee
Age: 61 SVP Since 2013
919 859-1314 www.biocryst.com
Babu has served as the Company?s Vice President ? Drug Discovery since 1992. Prior to joining BioCryst, he served five years on the biochemistry faculty at the University of Alabama at Birmingham.
The company has return on total asset (ROA)
of (27.86) %
which means that it has lost $27.86 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (251.64) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 54.16 M in liabilities with Debt to Equity (D/E) ratio of 224.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. BioCryst Pharmaceuticals Inc has Current Ratio of 1.54 which is within standard range for the sector.
|Found 1 records|
|Reed Clark||Dimension Therapeutics Inc|
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. BioCryst Pharmaceuticals Inc (BCRX) is traded on NASDAQ in USA. It is located in NORTH CAROLINA, U.S.A and employs 70 people. BioCryst Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.